Locations
Laval, QC, Canada
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Seed
founded in
2019
Thryv Therapeutics is pioneering a precision medicine approach to treat conditions such as Congenital Long QT Syndrome, atrial fibrillation, and heart failure through the development of potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). The company focuses on innovative treatments that aim to improve the quality of life for patients with life-threatening conditions. With a strong commitment to research and development, Thryv is positioned to make significant advancements in the biotechnology sector, particularly in the realm of cardiovascular diseases. Their recent achievements include receiving FDA Orphan Drug Designation for their lead product, LQT-1213, which underscores their traction in the market and potential for growth.
Something looks off?On-site & Remote